GEN Exclusives

More »

The Lists

More »
Oct 2, 2012

Top 20 Molecular Millionaires

Which biopharma company leaders are raking in the most in shares?

Top 20 Molecular Millionaires

Among the millionaires who’ve made their fortunes by investing in biotech, these 20 top the list. [AlienForce - Fotolia.com]

  • #10. William C. Weldon

    Chairman, Johnson & Johnson

    Total value of common shares owned: $31,721,932

    486,682 common shares owned as of Feb. 28, 2012

    Closing price: $65.18

  • #9. James M. Cornelius

    Non-executive Chairman; CEO, 2008–10, Bristol-Myers Squibb

    Total value of common shares owned: $32,259,615.85

    994,133 common shares owned as of Feb. 28, 2012

    Closing price: $32.45

  • #8. Robert J. Hugin

    Chairman and CEO, Celgene

    Total value of common shares owned: $34,559,378.88

    438,126 common shares owned as of April 18, 2012

    Closing price: $78.88

  • #7. Kevin W. Sharer

    Chairman and CEO, Amgen

    Total value of common shares owned: $60,865,836.48

    901,449 common shares owned as of March 26, 2012

    Closing price: $67.52

  • #6. Joseph Jimenez

    CEO, Novartis

    Total value of common shares owned: $61,103,909.76

    1,056,033 common shares owned as of Jan. 19, 2012

    Closing price: $57.87 [Converted Sept. 27, 2012, from CHF 54.20 closing share price]

  • #5. Miles D. White

    Chairman and CEO, Abbott Laboratories

    Total value of common shares owned: $64,833,849.15

    1,197,301 common shares owned as of Jan. 31, 2012

    Closing price: $54.15

  • #4. John C. Martin, Ph.D.

    Chairman and CEO, Gilead Sciences

    Total value of common shares owned: $88,767,251.10

    1,949,215 common shares owned as of Feb. 29, 2012

    Closing price: $45.54

  • #3. Leonard Bell, M.D.

    CEO, Alexion Pharmaceuticals

    Total value of common shares owned: $93,541,944.15

    1,050,915 common shares owned as of March 16, 2012

    Closing price: $89.01

  • #2. Leonard S. Schleifer, M.D., Ph.D.

    President and CEO, Regeneron Pharmaceuticals

    Total value of common shares owned: $257,315,504.13

    2,119,393 common shares owned as of April 11, 2012

    Closing price: $121.41

  • #1. Phillip Frost, M.D.

    Chairman, Teva Pharmaceutical Industries

    Total value of common shares owned: $548,379,553

    13,587,204 common shares owned as of Dec. 31, 20112

    Closing price: $40.36


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?